<DOC>
	<DOCNO>NCT01227239</DOCNO>
	<brief_summary>The purpose study assess safety efficacy S-1 oxaliplatin combine radiation Phase I/II study . The purpose study follow , - In phase I , determine dose limit toxicity ( DLTs ) maximum tolerate dose ( MTD ) . - In phase II , evaluate antitumor effect ( pCR rate ) safety .</brief_summary>
	<brief_title>Preoperative S-1/OHP With Radiation Therapy Low-lying Rectal Carcinoma Neo-adjuvant Setting</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Patients confirm locally advanced nonmetastatic rectal adenocarcinoma ( clinical stage T3 , anyN T4 , anyN ) 2 . Possible R0 resection 3 . Received prior therapy 4 . Performance status ( ECOG ) 01 5 . Normal organ marrow function . 6 . Sufficient oral intake 1 . History serious allergic reaction 2 . Patients without serious complication sensory neurotoxicity serious diarrhea ( watery stool ) . 3 . Female pregnancy lactation 4 . Have another malignancy past 5 year except early stage cancer cure local treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>